Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Response to the HEPLISAV-B Hepatitis B Vaccine in Treatment Naive Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's -Tyrosine Kinase Inhibitor (BTK-I)

Next Previous
Trial Profile

Response to the HEPLISAV-B Hepatitis B Vaccine in Treatment Naive Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's -Tyrosine Kinase Inhibitor (BTK-I)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary)
  • Indications Hepatitis B
  • Focus Pharmacodynamics

    • Most Recent Events

    • 17 Dec 2020 Status changed from recruiting to completed.
    • 01 Dec 2020 Results (n=121) of two studies (NCT03685708 (Hep-CpG) and NCT03702231 (RZV)) assessing effect of BTKi's on de novo immune response against recombinant hepatitis B vaccine and recall response against recombinant zoster vaccine in chronic lymphocytic leukemia patients who were treatment naive or on Bruton's -Tyrosine Kinase Inhibitor, published in the Blood.
    • 20 Aug 2020 Planned number of patients changed from 123 to 108.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top